RESEARCH
Tasman Oncology Research Ltd is a patient focused research company dedicated to conducting clinical trials to help both insured and uninsured patients gain access to new oncology pharmaceuticals only accessible or affordable through a trial opportunity. Tasman Oncology Research is a well-resourced and well-published clinical trials unit; with a team of five clinical trial-coordinators and two data entry staff with their their own dedicated suite next to the day infusion unit.
CLINICAL TRIALS
Why do we participate in clinical trials?
Tasman Oncology Research Ltd is a patient focused research company dedicated to conducting clinical trials to help both insured and uninsured patients gain access to new oncology pharmaceuticals only accessible or affordable through a trial opportunity. All trial related consultations and procedures are provided at no cost to the patient. All research conducted by the Tasman Oncology Research is conducted in accordance with applicable regulatory requirements and the internationally recognised standards of Good Clinical Practice.
Through our close partnerships with clinical research organisations, we coordinate a number of Phase One, Two and Three multi-site international clinical trials which are outlined on the Current Clinical Trials page
If you would like more information regarding clinical trial opportunities, please speak with your doctor or one of our research coordinators. The coordinators can be reached directly on (07) 5613 2484, or research@tasmanhealthcare.com.au.
RESEARCH FACILITIES
Tasman Oncology Research brings together an experienced team of research coordinators, nurses, data managers and scientists to support an advanced clinical trial unit.
Our clinical trials unit is staffed by a highly qualified group of research coordinators who are certified in Good Clinical Practice through ARCS Australia and also hold IATA certification for the transportation of dangerous goods. All coordinators have extensive experience using IVRS/IWRS and eCRF systems. We have a dedicated Quality Manager on team ensuring compliance with ICH-GCP guidelines, TGA regulations, sponsor requirements, protocol requirements and Tasman Health Care SOPs. We have a strong working relationship with Bellberry HREC for efficient study start-up timelines and lead site responsibilities.
Staff are familiar and have up-to-date training in several eCRF platforms including InForm, Medidata RAVE, Oracle RDC and eClinical OS. They are collectively experienced in using patient electronic diaries and imaging transfer software including AGMedNet and Bioclinica.
In addition, the research coordinators have laboratory experience and are competent in all aspects of specimen collection, preparation, handling and shipping.
Tasman Oncology Research views continual education and training as a key investment strategy. Therefore we ensure staff are qualified to perform procedures through ongoing training and professional development. All investigators, sub-investigators and clinical research staff attend both internal and external compulsory training, as well as undertaking further education specific to the nature of this work.
Our monthly quality meetings monitor the need for training and Clinical Research staff conduct regular in-services on the requirements and conduct of clinical research. In particular the specific requirements of individual studies for staff from other departments involved in the conduct of clinical research.
CURRENTLY RECRUITING CLINICAL TRIALS
Please speak to your treating oncologist or GP to investigate whether there may be any current clinical trials you may be suitable for. The following clinical trials are currently open for recruitment:
OPENING SOON – IGM-8444-001
Colorectal Cancer
IGM-8444+FOLFIRI (± bevacizumab).
ONC-392-001
TNBC, NSCLC, Melanoma, HNSCC
ONC-392 (anti-CTLA-4 mAb) as a Single Agent and in Combination with Pembrolizumab.
ONC-392-001 – ClinicalTrials.gov
MK-7684A-010 (Keyvibe-010)
Stage II-IV Melanoma
Pembrolizumab/vibostolimab (anti-TIGIT) to pembrolizumab.
MK-7684-10 – ClinicalTrials.gov
MK3475-02B
Stage III Melanoma
First line investigational agents in advanced disease.
BAY 88-8223/20510
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Standard Dose of Radium-223 Dichloride versus Standard Doses of Novel Anti-Hormonal Therapy.
CAIN457R12301
Giant Cell Arteritis (GCA)
Secukinumab verse placebo, in combination with glucocorticoid taper regimen.
CAIN457R12301 – ClinicalTrials.gov
CAIN457C22301
Polymyalgia Rheumatica (PMR)
Secukinumab verse placebo, in combination with glucocorticoid taper regime.
AI-061
Advanced Solid Tumours
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
ASND0029 (IL-Believe)
Locally Advanced or Metastatic Solid Tumor Malignancies
TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, TransCon TLR7/8 Agonist, or Chemotherapy.
CF33-hNIS-002
Basket = metastatic or advanced solid tumours
CF33-hNIS (hNIS – human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab.
CF33-hNIS-002 – ClinicalTrials.gov
CA115-001
PENDING – OPEN FROM 28 AUGUST
Advanced Solid Tumours and Non-Small Cell Lung Cancer
BMS-986442 in combination with nivolumab (with or without chemotherapy).
CA115-001 – ClinicalTrials.gov
SURF301
Cancers with FGFR3 activating gene alterations
TYRA-300, a fibroblast growth factor receptor (FGFR) 3-selective tyrosine kinase inhibitor.
IMAT
Stage I-III Merkel Cell Carcinoma
Adjuvant Avelumab or placebo given for 6 months in patients with stage I-III MCC treated with definitive local therapy (surgery and/or radiotherapy).
MS100070-0119 (Javelin)
Untreated, unresectable, locally advanced, or metastatic urothelial cancer
Group A Avelumab maintenance (control)
Group B avelumab + sacituzumab govitecan maintenance
Group C avelumab + M6223 (anti-TIGIT) maintenance
Group D avelumab + NKTR-255 (IL-15 agonist) maintenance
Please contact our research rooms on (07) 5613 2484 for further information, or follow the clinicaltrials.gov hyperlink for each particular study.